Wolfe Research Begins Coverage on Twist Bioscience (NASDAQ:TWST)

Equities researchers at Wolfe Research assumed coverage on shares of Twist Bioscience (NASDAQ:TWST) in a research note issued to investors on Friday. The brokerage set an “outperform” rating and a $60.00 price target on the stock. Wolfe Research’s price target points to a potential upside of 26.61% from the company’s previous close.

A number of other equities research analysts also recently issued reports on TWST. Evercore ISI upped their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. TD Cowen reaffirmed a “buy” rating and issued a $58.00 price target on shares of Twist Bioscience in a report on Tuesday, November 26th. Robert W. Baird boosted their price objective on Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 19th. Scotiabank raised their price objective on Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a research note on Tuesday, November 19th. Finally, Leerink Partners boosted their target price on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $51.90.

Twist Bioscience Price Performance

NASDAQ:TWST opened at $47.39 on Friday. The company has a market cap of $2.81 billion, a price-to-earnings ratio of -13.16 and a beta of 1.82. Twist Bioscience has a 1 year low of $27.41 and a 1 year high of $60.90. The stock’s 50 day simple moving average is $44.85 and its two-hundred day simple moving average is $46.60.

Insiders Place Their Bets

In related news, CEO Emily M. Leproust sold 2,216 shares of the company’s stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $52.70, for a total value of $116,783.20. Following the completion of the sale, the chief executive officer now directly owns 674,718 shares of the company’s stock, valued at $35,557,638.60. This represents a 0.33 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Paula Green sold 1,057 shares of the firm’s stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $41.56, for a total transaction of $43,928.92. Following the transaction, the senior vice president now directly owns 121,013 shares in the company, valued at $5,029,300.28. This trade represents a 0.87 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 101,787 shares of company stock worth $4,584,508 in the last three months. Corporate insiders own 3.92% of the company’s stock.

Hedge Funds Weigh In On Twist Bioscience

Institutional investors have recently bought and sold shares of the business. Wilmington Savings Fund Society FSB bought a new position in Twist Bioscience in the third quarter worth about $34,000. Signaturefd LLC raised its stake in shares of Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after acquiring an additional 306 shares in the last quarter. EdgeRock Capital LLC purchased a new stake in Twist Bioscience during the second quarter valued at approximately $43,000. Blue Trust Inc. boosted its stake in Twist Bioscience by 2,912.8% in the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after acquiring an additional 1,136 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale purchased a new position in Twist Bioscience in the second quarter worth $61,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.